December 25, 2013
Daiichi Sankyo has filed for approval of its oral factor Xa-inhibitor Lixiana (edoxaban) with additional indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism (VTE), the company said on December 19. The latest application covers two indications: 1) the...read more